Gary Stetz Sells 12,500 Shares of Hillstream Biopharma (NASDAQ:CNTN) Stock

Posted by Caroline Horne on May 29th, 2026

Hillstream Biopharma Inc. (NASDAQ:CNTN – Get Free Report) Director Gary Stetz sold 12,500 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $3.47, for a total transaction of $43,375.00. Following the sale, the director owned 134,175 shares in the company, valued at $465,587.25. This trade represents a 8.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Hillstream Biopharma Price Performance

CNTN stock opened at $3.11 on Friday. Hillstream Biopharma Inc. has a 52 week low of $1.08 and a 52 week high of $9.08. The company has a market cap of $217.11 million, a P/E ratio of -2.70 and a beta of 1.44. The stock’s 50-day moving average is $3.31.

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CNTN. Wall Street Zen raised Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

View Our Latest Report on CNTN

About Hillstream Biopharma

(Get Free Report)

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.